RNAZ logo

TransCode Therapeutics, Inc.

RNAZ
Healthcare|Biotechnology|US
$1.49
-0.02 (-1.32%)
DCF Value
$26.00
Cash / Share
$8.95
Next Earnings Report
Nov 18, 2026
Financing Filings (last 12 months)
4
Shelf registrations / offering prospectuses — latest Jul 20, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (1)

Dec 2030
Est. completion
P1P2HER2-positive Breast Cancer
PRE-ISPY Phase I/II Oncology Platform Program
NCT05868226n=280

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Sep 2025
P1P2
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
NCT06260774

Recent Press Releases

TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
Oct 28, 2026 · PRNewsWire
TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
Oct 26, 2026 · PRNewsWire
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
Oct 19, 2026 · PRNewsWire
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Oct 13, 2026 · Business Wire
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
Sep 28, 2026 · PRNewsWire
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
Sep 22, 2026 · PRNewsWire
TransCode Therapeutics Announces Leadership Transition
Sep 10, 2026 · PRNewsWire
TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis
Aug 31, 2026 · PRNewsWire

SEC Filings (101)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 28, 20268-KMaterial eventDocumentIndex
Oct 1, 20268-KMaterial eventDocumentIndex
Sep 28, 20268-KMaterial eventDocumentIndex
Sep 11, 20268-KMaterial eventDocumentIndex
Aug 14, 202610-QQuarterly reportDocumentIndex
Aug 3, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Aug 3, 20268-KMaterial eventDocumentIndex
Jul 28, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 28, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 28, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 27, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Jul 23, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Jul 20, 2026424B3Offering prospectusDocumentIndex
Jul 20, 2026424B3Offering prospectusDocumentIndex
Jul 20, 20268-KMaterial eventDocumentIndex
Jul 17, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Jul 17, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jul 17, 20268-KMaterial eventDocumentIndex
Jul 2, 20268-KMaterial eventDocumentIndex
Jun 18, 20268-KMaterial eventDocumentIndex
Jun 3, 20268-KMaterial eventDocumentIndex
Jun 2, 2026ARSAnnual report to holdersDocumentIndex
Jun 2, 2026DEF 14AProxy / shareholder voteDocumentIndex
Jun 1, 20268-KMaterial eventDocumentIndex
May 26, 2026DEFA14AProxy / shareholder voteDocumentIndex
May 26, 20268-K/AMaterial eventDocumentIndex
May 22, 20268-KMaterial eventDocumentIndex
May 19, 2026EFFECTDocumentIndex
May 19, 2026EFFECTDocumentIndex
May 15, 202610-QQuarterly reportDocumentIndex
May 8, 2026PRE 14AProxy / shareholder voteDocumentIndex
Apr 30, 2026S-3Shelf registrationDocumentIndex
Apr 30, 202610-K/AAnnual reportDocumentIndex
Apr 20, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 15, 202610-KAnnual reportDocumentIndex
Apr 7, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 7, 20268-KMaterial eventDocumentIndex
Mar 31, 2026NT 10-KDocumentIndex
Mar 3, 2026DEFA14AProxy / shareholder voteDocumentIndex
Mar 3, 20268-KMaterial eventDocumentIndex